Don’t miss – Page 185 – Endpoints News

SIGN UP

Don't get too excited about Eli Lilly's upcoming Alzheimer's readout just yet, R&D chief cautions

4 years ago

Doudna-founded CRISPR upstart bags $45M for new Cas research, extends its reach into therapeutics

4 years ago

Josh Bilenker’s team at Eli Lilly chops 3 cancer drug programs in pipeline cleanup as their $1.6B IL-10 effort flames out

4 years ago

Sanofi polishes rare disease profile as Niemann-Pick drug scores promising PhII/III data — there's just one question

4 years ago

'What's he going to do? He's going to date his wife more!' Steve Holtzman on Decibel and leaving biotech (again)

4 years ago

Novartis rethinks CML strategy for next-gen allosteric drug due for a pivotal readout later this year

4 years ago

Putting buybacks on hold, Pfizer’s CEO is plotting a string of important PhII deals in the year ahead. You’ve been alerted

4 years ago

How do American scientists get embroiled in China scandals? Moffitt investigation sheds some light

4 years ago

Laurence Reid returns as CEO of Decibel Therapeutics — as Steve Holtzman retires

4 years ago

Top Harvard chemist caught up in FBI’s 'Thousand Talents' dragnet, accused of lying about Chinese connections, pay

4 years ago

Pfizer axes 6 early to late-stage cancer studies from the pipeline — with one other cut for sickle cell disease

4 years ago

Ex-Novartis CEO Joe Jimenez is taking another crack at opening a new chapter in his career — and that includes a new board seat and a $250M startup

4 years ago

Acceleron resurrects blockbuster hopes for sotatercept with positive PhII — and shares rocket up

4 years ago

Civica and Blue Cross Blue Shield launch new venture to lower generic prices

4 years ago

Short attacker Sahm Adrangi draws crosshairs over a favorite of Sanofi’s new CEO — with PhII data looming

4 years ago

AbbVie and Allergan divestitures are in, and an old AstraZeneca drug comes home

4 years ago

Bruce Booth and Samantha Truex's latest venture aims just above Humira

4 years ago

A $1B-plus drug stumbles into another big PhIII setback — this time flunking futility test — as FDA hold remains in effect for Ipsen

4 years ago

Roche's checkpoint player Tecentriq flops in another bladder cancer subset

4 years ago

2019 a 'transformative year' for pharma M&A. Is that a good thing?

4 years ago

Eli Lilly’s $1.6B cancer drug failed to spark even the slightest positive gain for patients in its 1st PhIII

4 years ago

PureTech bags $200M from sale of Karuna shares — still sizzling from promising schizophrenia data

4 years ago

The FDA has devalued the gold standard on R&D. And that threatens everyone in drug development

4 years ago

New players are jumping into the scramble to develop a vaccine as pandemic panic spreads fast

4 years ago

First page Previous page 182 183 184185186 187 188 Next page Last page